Key Highlights
- The backdrop against which these eight companies are trading in September 2026 is one of selective investor appetite rather than broad enthusiasm. UK-listed healthcare and life-sciences businesses, particularly at the smaller end, have spent much of the post-pandemic period contending with tighter financing conditions, a more demanding attitude to cash burn, and a public-market audience that rewards demonstrable Revenue and Margin progress more reliably than it rewards narrative.
- ECO Animal Health Group plc (LSE:EAH): The near-term calendar is dominated by the company’s September annual general meeting, at which non-executive director Frank Armstrong is due to step down.
- Kromek Group plc (LSE:KMK): As at 11 September 2026 the full-year results for the year ended 30 April 2026 had not yet been published but were imminent, the prior-year finals having appeared on 16 September 2025.
- Oxford BioDynamics Plc (LSE:OBD): The most consequential recent event was the rescue financing completed in August 2026.
- Applied Nutrition plc (LSE:APN): The company’s full-year results for the year ended 31 July 2026, published on 26 August 2026, beat expectations and were accompanied by a raised outlook.
- AOTI, Inc. (LSE:AOTI): On 27 July 2026 the company issued a trading statement for the six months to 30 June 2026.
- Abingdon Health plc (LSE:ABDX): On 29 July 2026 the company issued a trading update covering the half-year to 30 June 2026 and the full financial year.
- RUA Life Sciences plc (LSE:RUA): Interim results for the six months to 31 March 2026, published on 30 June 2026, showed revenue of £2.75m, up 6.1%, a gross margin of around 75%, and a return to positive adjusted EBITDA of approximately £76,000, helped by lower administrative costs.
- Poolbeg Pharma PLC (LSE:POLB): On 13 July 2026 the company announced that the first patient had been dosed in the POLB 001 “TOPICAL” trial, an open-label study in cancer patients receiving immunotherapy across UK cancer centres including The Christie, the Royal Marsden, UCLH and University Hospitals Birmingham.
British investors scanning the healthcare and life-sciences corner of the London market in September 2026 are confronted with an unusually broad spread of Business models, all clustered at the smaller end of the Capitalisation scale. The eight companies examined here range from an animal-health group shipping antibiotics and poultry vaccines into more than seventy markets, through a radiation-detection specialist supplying medical imaging and defence customers, to a clutch of diagnostics, wound-care and clinical-stage drug developers whose fortunes hinge on reimbursement decisions and trial read-outs expected before the year is out. Only one of them, the sports-nutrition manufacturer Applied Nutrition, trades on the London Stock Exchange’s Main Market; the rest are quoted on AIM, the junior market where Liquidity is thinner, disclosure cadences are lighter and share prices can swing sharply on a single announcement.
A word on the headline is warranted at the outset. The “FTSE” framing used here is editorial shorthand for prominent London-listed UK health names, not a statement that any of these businesses sits in the FTSE 100 or FTSE 250. Of the eight, Applied Nutrition (LSE:APN) is the only one with a verified place in a FTSE index series: it is a constituent of the FTSE SmallCap index and therefore of the broader FTSE All-Share. The other seven — ECO Animal Health (LSE:EAH), Kromek (LSE:KMK), Oxford BioDynamics (LSE:OBD), AOTI (LSE:AOTI), Abingdon Health (LSE:ABDX), RUA Life Sciences (LSE:RUA) and Poolbeg Pharma (LSE:POLB) — are AIM-quoted and are not verified as current FTSE index constituents. AOTI is a particular case worth flagging early: it is a US-incorporated (Delaware) wound-care MedTech company that chose to list in London, joining AIM in June 2024. It is neither a FTSE name nor a Main Market name.
The aim is to lay out what each business does, what it has reported during 2026, what is financially verifiable from its own disclosures, and what investors following the sector may reasonably choose to monitor in the remaining weeks of September and beyond. Where a figure, date or development is not confirmed in the underlying company disclosures, that is stated plainly rather than filled in. Several of these names carry the kind of going-concern, reimbursement or binary-trial risk that can reshape the Investment case overnight, and those risks are spelled out company by company. With that framing established, the wider market context comes first.
UK Health & Life-Sciences Market Backdrop
The backdrop against which these eight companies are trading in September 2026 is one of selective investor appetite rather than broad enthusiasm. UK-listed healthcare and life-sciences businesses, particularly at the smaller end, have spent much of the post-pandemic period contending with tighter financing conditions, a more demanding attitude to cash burn, and a public-market audience that rewards demonstrable revenue and margin progress more reliably than it rewards narrative. That environment flatters commercially generating companies and punishes those still some distance from revenue, and the spread of outcomes across this group reflects exactly that division.
Consumer health and sports nutrition occupy one of the more buoyant sub-sectors. Demand for protein, functional foods and performance supplements has proved comparatively resilient, supported by structural interest in fitness, preventative health and everyday wellness. The category is, however, crowded and discretionary: Brand strength, retail distribution and the ability to scale Manufacturing efficiently separate the winners from the also-rans, and margins can be pressured when companies push into new geographies or acquire lower-margin businesses to buy growth.
Wound care and medical technology sit at the other end of the visibility spectrum, where the decisive variable is reimbursement rather than consumer demand. In the United States, coverage decisions by the Centers for Medicare & Medicaid Services — and by the Department of Veterans Affairs and individual state Medicaid programmes — can make or break the commercial trajectory of a device. A favourable national or local coverage determination opens a large insured population; an unfavourable or delayed one can leave a clinically validated product commercially stranded. For UK-listed medtech companies earning predominantly US revenue, this also layers currency translation onto the reimbursement question.
Diagnostics has had a harder time. The extraordinary demand of the Pandemic years has normalised, and companies built around rapid testing or molecular diagnostics have had to rebuild more durable commercial models. For contract developers and manufacturers the route back has run through named customer programmes and services revenue; for proprietary-test developers it has run through the slower, evidence-heavy process of winning clinical-guideline inclusion and payer reimbursement, during which cash discipline is paramount.
Animal health remains a comparatively defensive niche, underpinned by global protein consumption and the Economics of livestock production. It is not without cyclicality — pig-cycle economics, disease outbreaks and regional demand swings all feed through — and it carries its own regulatory theme in the form of sustained pressure to reduce antimicrobial use in food-producing animals. That pressure is simultaneously a headwind for antibiotic franchises and a tailwind for the Vaccine pipelines that companies are building as a longer-term substitute.
Clinical-stage biotech is where financing conditions bite hardest. With no revenue to fall back on, development-stage companies depend on periodic Equity raises, grant income or partnering deals to fund trials. The prevailing preference among such companies in 2026 has been capital-efficient models: running lean, prioritising one or two lead assets, and seeking pharmaceutical partners to shoulder the cost of late-stage development. Investors in this part of the market are effectively Underwriting binary events — a trial read-out, a regulatory designation, a licensing signature — and pricing reflects that.
Conditions on AIM itself form the connective tissue across most of this group. The junior market has endured a prolonged stretch of subdued sentiment, with modest liquidity, episodic fundraising and a premium placed on companies that can show a path to profitability or a clearly funded runway. Micro-cap names in particular can see heavy dilution when they raise, and can trade on very wide spreads. Sterling’s level matters for the dollar-earning businesses in the group, flattering or denting reported results on translation. And the domestic policy backdrop — NHS procurement priorities, UK regulatory pathways for diagnostics and devices, and the broader appetite to pilot novel tests within the health service — shapes the opportunity set for the UK-facing names. None of these themes guarantees any particular outcome for the companies below; they simply describe the weather in which each is operating.
ECO Animal Health Group plc (LSE:EAH)
Company overview
ECO Animal Health is an AIM-quoted animal-health group specialising in veterinary pharmaceuticals and, increasingly, poultry vaccines. It is not verified as a current FTSE index constituent. Its flagship product is Aivlosin, a macrolide antimicrobial used to treat respiratory and enteric disease in pigs and poultry, sold across more than seventy markets. Alongside that established Franchise the group is building a growing vaccine business under the ECOVAXXIN brand. Its largest geographies are North America, China and Japan, and Latin America. As of 10 September 2026 the company carried a Market Capitalisation of approximately £69.8m, with shares around 103p.
Latest September 2026 developments
The near-term calendar is dominated by the company’s September annual general meeting, at which non-executive director Frank Armstrong is due to step down. Ahead of that, the group had already confirmed the appointment of Dr Andrew Winder as Head of Business Development in May 2026, a hire that signals continued emphasis on pipeline and commercial expansion. Management’s stated outlook is for the financial year to March 2027 to come in line with market expectations, with trading second-half weighted.
Major 2026 developments
The defining event of the year was the full-year results for the twelve months to 31 March 2026, published on 15 July 2026, which beat expectations. Revenue rose to £87.5m from £79.6m the prior year, up 10% as reported and 14% on a constant-currency basis (£91.0m). Gross Profit reached £42.5m, lifting the gross margin to 48.6% from 45.1%. Operating profit was £5.7m, adjusted EBITDA £8.5m (up 16%), and profit before tax £5.4m (up 35%). Earnings Per Share climbed to 3.26p from 2.49p. The group finished the period with net cash of £25.4m and paid no dividend, choosing to reinvest. On the vaccine side, ECOVAXXIN MS, a Mycoplasma synoviae poultry vaccine, received EU approval in December 2025 and was launched in July 2026, while ECOVAXXIN MG secured a favourable USDA safety assessment in March 2026. In June 2026 the group renewed its banking facilities for a further five years, comprising a £10m revolving Credit Facility and a £5m overdraft, both undrawn.
Products, pipeline and technology
The commercial core remains Aivlosin, an approved antimicrobial with broad geographic reach. The strategic growth story, however, is the vaccine franchise: the group is targeting up to nine further products for US and EU approval within the next five to six years, with ECOVAXXIN MS and MG the most advanced. Regional revenue in the latest year showed North America at £26.1m (up 22%), Latin America at £18.8m (up 15%) and China and Japan at £24.1m (up 5%), with South and South-East Asia at £11.1m (down 7%) and Europe at £4.8m (down 2%).
Financial position
The Balance Sheet is a relative strength, with £25.4m of net cash, no Dividend outflow and freshly renewed, undrawn banking facilities. Margins are moving in the right direction, and the profit-before-tax growth of 35% outpaced revenue, indicating operating leverage.
What investors may be watching
Attention is likely to centre on the anticipated US approval of ECOVAXXIN MS, which management expects by the end of the 2026 calendar year, and on the EU roll-out scheduled across the third quarter of 2026 to the first quarter of 2027. An R&D day is planned for autumn 2026. Investors may also monitor a recovery in the softer Asian markets and any licensing or M&A activity.
Key risks
The business remains materially reliant on an antibiotic product at a time of sustained pressure to curb antimicrobial use in food-producing animals. Vaccine approvals carry regulatory and timing risk. Foreign-exchange movements affect reported results, livestock and pig-cycle economics and disease outbreaks introduce volatility, and the recent softness in Asian markets has yet to reverse.
Kromek Group plc (LSE:KMK)
Company overview
Kromek is a County Durham-based developer and manufacturer of cadmium-zinc-telluride (CZT) radiation-detection technology, quoted on AIM and not verified as a current FTSE index constituent. It operates two divisions: CBRN Detection, supplying chemical, biological, radiological and nuclear detection equipment to defence and homeland-security customers; and Advanced Imaging, supplying detector components for medical imaging, including a Supply relationship with Siemens Healthineers. The company is commercial-stage, UK-based with US operations. As of 10 September 2026 its market capitalisation stood at approximately £47.8m, with shares around 7.1p to 7.5p.
Latest September 2026 developments
As at 11 September 2026 the full-year results for the year ended 30 April 2026 had not yet been published but were imminent, the prior-year finals having appeared on 16 September 2025. The most recent announcements were operational rather than financial: an August 2026 statement concerning delivery of a third contract milestone and the grant of Options (6 August), and a director share purchase (3 August).
Major 2026 developments
On 12 May 2026 the company issued a full-year trading update for the year to 30 April 2026, reporting revenue and profit before tax in line with market expectations and citing consensus figures of roughly £27.2m of revenue and about £2.15m of profit before tax. During the second half of the financial year Kromek secured £8.8m of new orders across both divisions, including a major new Advanced Imaging order from an existing customer. CBRN grew year on year, and Advanced Imaging showed what the company described as good underlying growth excluding the Siemens agreement.
Products, pipeline and technology
The company’s differentiator is its CZT detector technology, which underpins both the medical-imaging components it supplies and the radiation-detection instruments used in security and defence applications. The Siemens Healthineers relationship is a notable anchor in Advanced Imaging. The business is commercial rather than developmental, but its revenue is project- and contract-driven.
Financial position
On the basis of the May trading update, consensus pointed to full-year revenue of about £27.2m and profit before tax of roughly £2.15m. Detailed gross margin, EBITDA, cash and net-debt figures await the full-year finals and are unverified at the time of writing.
What investors may be watching
The imminent FY2026 audited results, expected in September 2026, are the obvious near-term focus, together with the pace of order-book conversion and the potential for multi-year government framework or biosecurity contracts.
Key risks
Kromek’s revenue is lumpy and contract-driven, with explicit sensitivity to government and defence procurement timing; the company has itself flagged the risk of governmental contract delays. Advanced Imaging carries customer-concentration risk, supply-chain disruption is a live concern, and the group has a history of thin profitability.
Oxford BioDynamics Plc (LSE:OBD)
Company overview
Oxford BioDynamics is an AIM-quoted molecular-diagnostics company built around epigenetics and 3D genomics, and it is not verified as a current FTSE index constituent. It commercialises the proprietary EpiSwitch 3D-genomics platform, which uses chromosome-conformation signatures to develop blood-based diagnostic and predictive tests. As of 10 September 2026 its market capitalisation was approximately £4.9m, placing it firmly in micro-cap territory, with the stock heavily diluted following an August 2026 rescue placing and trading around 0.11p to 0.12p, down roughly 73% over the prior year. It is early commercial-stage with material going-concern pressure.
Latest September 2026 developments
The most consequential recent event was the rescue financing completed in August 2026. On 10 August the company announced a £9.15m gross (approximately £8.4m net) placing of 9.15 billion new shares at £0.001 each — around 68.1% of the enlarged share capital, at a 9.1% discount to the 7 August close — together with 260.85m broker warrants at £0.002. The accompanying circular warned that cash would otherwise have been exhausted by early September 2026. Shareholders approved the raise at a general meeting on 26 August 2026. Proceeds are earmarked to fund Orion partnerships, PSE growth including a UK NHS pilot, the CiRT evidence programme, pipeline work including a colorectal-cancer study, and at least twelve months of working capital.
Major 2026 developments
Interim results for the six months to 31 March 2026, published on 30 June 2026, showed revenue of £0.69m, up 17% year on year from £0.59m, with PSE test sales up 126% year on year (1,788 tests, taking the cumulative total above 5,000). The operating loss of £4.68m was 20% narrower than the prior year, and cash stood at £2.51m at 31 March 2026, with the board flagging material uncertainty over Going Concern and the need for around £3m of new equity by late August 2026. Richard Compton was appointed chief executive in June 2026, the EpiSwitch Orion cloud platform was launched in March 2026 with commercial discussions under way with three large pharmaceutical companies, and an ME/CFS blood test was targeted for commercial availability before the end of 2026.
Products, pipeline and technology
The EpiSwitch platform supports a suite of diagnostic and predictive tests — not therapeutic drugs. The lead products are PSE, a prostate-screening test, and CiRT, a Checkpoint-inhibitor Response Test for immuno-oncology. Direct sales of CiRT are restricted pending an application for inclusion in the NCCN Guidelines, and the associated PROWES study has been paused. The recently launched Orion cloud platform, an ME/CFS test and a colorectal-cancer programme round out the pipeline.
Financial position
First-half FY26 revenue was £0.69m against an operating loss of £4.68m, with pre-placing cash of £2.51m at 31 March 2026 topped up by roughly £8.4m net in August 2026. The share count is now heavily diluted following that raise.
What investors may be watching
The post-placing runway of at least twelve months provides breathing room. Beyond that, monitorable items include any Orion pharma-partnership signings, the UK NHS PSE pilot, the NCCN guideline decision for CiRT and the targeted ME/CFS test launch before the end of 2026.
Key risks
The standout risks are severe going-concern and financing risk and the extreme dilution already incurred. Revenue is very low relative to cash burn, commercial progress is dependent on reimbursement and guideline adoption, and micro-cap liquidity is thin.
Applied Nutrition plc (LSE:APN)
Company overview
Applied Nutrition is a sports-nutrition and consumer-health manufacturer that listed on the London Stock Exchange’s Main Market in October 2024. It is a verified constituent of the FTSE SmallCap index and therefore of the FTSE All-Share — the only company in this group with a confirmed place in a FTSE index series. It develops and manufactures more than 120 SKUs of protein powders, pre-workouts, hydration products and vitamins under brands including Applied Nutrition, ABE, BodyFuel and Endurance, operating a vertically integrated facility in Knowsley, Merseyside and selling into more than 85 countries through gyms, specialist retail, mainstream grocery and international distribution. As of 9 September 2026 its market capitalisation was approximately £732m, with shares around 293p against a 52-week range of roughly 158p to 356p.
Latest September 2026 developments
The company’s full-year results for the year ended 31 July 2026, published on 26 August 2026, beat expectations and were accompanied by a raised outlook. Revenue came in at approximately £160m, up around 50% year on year, with adjusted EBITDA of roughly £43.3m, up about 40%, both ahead of consensus. Initial FY27 guidance was pitched above consensus, and the shares rose around 5% on the day to about 338p. The reported FY26 beat was measured against S&P Global Consensus as referenced by Investing.com — a consensus reference, not a named-broker rating.
Major 2026 developments
Interim results for the six months to 31 January 2026, published on 23 March 2026, showed revenue of £74.5m, up 56.5%, gross profit of £34.8m at a 46.7% margin, adjusted EBITDA of £21.5m, up 55.8%, profit before tax of £20.9m, up 77%, and earnings per share of 6.2p, with net cash of £26.4m. On 1 June 2026 the company announced a $16m (approximately £12m) cash Acquisition of US peer Nutrablend Group, based in Buffalo, New York, bringing the Basic Supplements and GR8 Lifestyle brands and around 100 staff. The same update upgraded FY26 revenue guidance to about £148m excluding Nutrablend and unveiled a Mondelez International licensing deal — AN Supps in collaboration with SOUR PATCH KIDS and SWEDISH FISH — rolling into roughly 2,200 Walmart and 1,300 GNC stores from August 2026. No dividend is expected before FY27.
Products and commercial strategy
The product range spans protein, pre-workout (notably the ABE brand), hydration, ready-to-drink products and a broad 40-plus range. Strategy centres on US expansion, a new US manufacturing hub following the Nutrablend deal, out-licensing arrangements such as high-protein foods for Morrisons, and capacity expansion targeting around £300m of annual revenue capability.
Financial position
FY26 revenue of approximately £160m and adjusted EBITDA of about £43.3m, with first-half net cash of £26.4m, point to a strongly cash-generative business. The Nutrablend acquisition was funded from existing resources, and Nutrablend is expected to add at least $30m of revenue in FY27 at a high-single-digit EBITDA margin.
What investors may be watching
Points of focus include FY27 trading against the above-consensus guide, execution of the US expansion across Walmart, GNC, Mondelez and the Nutrablend integration, and completion of the new UK distribution and factory build-out, with a fit-out cost of £3.5m to £4.0m in FY27.
Key risks
The category is discretionary and crowded, exposing the company to consumer-demand and competitive pressures. US expansion brings margin dilution given Nutrablend’s lower margins, and there is execution risk on M&A and capacity build. The business relies on key retail relationships, and ownership remains concentrated following the IPO.
AOTI, Inc. (LSE:AOTI)
Company overview
AOTI is a US-incorporated (Delaware) wound-care medical-technology company that listed on AIM, where it trades as depositary interests under the RNS category “AOTI, Inc. (DI)”. It was admitted on 18 June 2024 in what was the largest AIM IPO by funds raised since 2021, and it operates from Oceanside, California and Galway, Ireland. It is not a FTSE name and not a Main Market name; nor is it verified as a current FTSE index constituent. Its subsector is wound-care medical technology. As of 10 September 2026 its market capitalisation was approximately £135m, with shares around 127.5p, re-rated higher during 2026 on Medicare coverage news; the IPO priced at 137p, raising £35.1m for a market capitalisation of roughly £140m at admission.
Latest September 2026 developments
On 27 July 2026 the company issued a trading statement for the six months to 30 June 2026. Revenue was approximately $35m, up from $31.8m in the prior-year period — 10% reported and 18% on an underlying basis excluding Arizona Medicaid — with cash of about $13.8m and net Debt of around $6.3m. The Veterans Administration accounted for roughly 57% of revenue, up about 15%, and Medicaid around 41%, up about 21% underlying. Critically, CMS issued a proposed Local Coverage Determination affirming topical-oxygen-therapy coverage for Medicare enrollees with diabetic foot ulcers, with finalisation expected within approximately one year following a 45-day comment period. Management said its growth trajectory would change materially only after the final Medicare LCD.
Major 2026 developments
The year’s defining corporate event is the proposed Medicare LCD, set against a backdrop of continued VA and Medicaid expansion and positive clinical-evidence read-outs on durable wound healing, with healing reported in around 65% of hard-to-treat cases according to the company and press coverage.
Products, pipeline and technology
AOTI commercialises TWO2, or Topical Wound Oxygen therapy, an intermittent, multi-modality home therapy for chronic wounds, especially diabetic foot ulcers, delivered through a device-and-consumables home-therapy model. The company claims roughly 75% of the topical-oxygen-therapy market, with revenue predominantly US-based through VA and Medicaid channels. It is commercial-stage.
Financial position
First-half 2026 revenue was approximately $35m, with cash of about $13.8m and net debt of around $6.3m. EBITDA and operating-profit detail are unverified, as this was a trading statement rather than full interim accounts.
What investors may be watching
The finalisation of the Medicare LCD, expected within roughly one year of the proposal, is the key potential value driver, as it would open nationwide Medicare reimbursement. Continued VA and Medicaid growth is the other monitorable theme.
Key risks
The business is heavily dependent on US reimbursement decisions, and a negative or delayed final LCD would materially affect the growth case. There is payer and channel concentration across the VA and Medicaid, a net-debt position, single-platform product concentration, and currency exposure given USD revenue against a GBP listing. There is no attributable, dated broker target; the house broker at IPO was Peel Hunt.
Abingdon Health plc (LSE:ABDX)
Company overview
Abingdon Health is an AIM-quoted in-vitro diagnostics company, also traded on OTCQB as ABDXF, and it is not verified as a current FTSE index constituent. It is a UK-based contract development and manufacturing organisation for lateral-flow rapid diagnostic tests, headquartered in York with additional operations in Doncaster and Madison, Wisconsin. Alongside manufacturing it offers regulatory consulting and analytical testing, serving infectious-disease, clinical, companion-diagnostic, animal-health and environmental applications. It is a commercial-stage services business. As of 12 August 2026, the most recent data point found, its market capitalisation was approximately £25m, with shares around 10p to 11p.
Latest September 2026 developments
On 29 July 2026 the company issued a trading update covering the half-year to 30 June 2026 and the full financial year. FY26 revenue rose 31% to £11.3m from £8.6m, with second-half revenue up 63% against the first half, and the business reaching adjusted EBITDA profitability in the second half of FY26. Cash stood at £2.9m, up from £1.9m a year earlier. Management flagged confidence in further growth in FY27 based on significant programmes previously announced.
Major 2026 developments
Earlier in FY26 the company published interim results for the half-year to 31 December 2025, after which the full-year trajectory accelerated into the second half, delivering the revenue surge and the EBITDA break-even noted above.
Products, pipeline and technology
Abingdon’s offering is services-led rather than a proprietary drug pipeline: lateral-flow assay development, contract manufacturing, regulatory and quality consultancy, and analytical and stability testing. Its value lies in converting named customer programmes into recurring manufacturing revenue.
Financial position
FY26 revenue for the year ended 30 June 2026 was £11.3m, up 31%, with the business reaching adjusted EBITDA profitability in the second half and cash of £2.9m. Full-year audited gross profit, operating result and net cash await the FY26 finals, expected around autumn 2026 and currently unverified.
What investors may be watching
The near-term focus is the FY26 audited finals, expected around autumn 2026, the conversion of named customer programmes into FY27 revenue growth, and whether the company can sustain EBITDA profitability.
Key risks
The revenue base is small and the company has a history of losses. Customer-programme concentration and timing are material, working-capital and cash headroom are constraints at a micro-cap, post-COVID normalisation of diagnostics demand is an ongoing adjustment, and the CDMO space is competitive.
RUA Life Sciences plc (LSE:RUA)
Company overview
RUA Life Sciences is a Scotland-based medical-device and biomaterials group, quoted on AIM and not verified as a current FTSE index constituent. Headquartered in Irvine, Ayrshire, it is built around the proprietary Elast-Eon biostable silicone-polyurethane polymer platform. The group has three pillars: RUA Medical, the profitable core encompassing contract manufacturing, device coatings and polymer supply; RUA Structural Heart, the AurTex polymer heart-valve programme that is being spun out; and Abiss, a urogynaecology Subsidiary being repositioned as a European specialist. As of 11 August 2026, the most recent data point found, its market capitalisation was approximately £16.8m, with shares around 26p to 28p.
Latest September 2026 developments
Interim results for the six months to 31 March 2026, published on 30 June 2026, showed revenue of £2.75m, up 6.1%, a gross margin of around 75%, and a return to positive adjusted EBITDA of approximately £76,000, helped by lower administrative costs. Management guided to core operations returning to profitability in the second half of the financial year.
Major 2026 developments
The group reported progress on the structural-heart spin-out, which it described as supported by third-party investment with a £10m valuation floor, and on the repositioning of Abiss as a specialist European urogynaecology business targeting a doubling of revenue over two years.
Products, pipeline and technology
The technology base is the Elast-Eon family of biostable polymers, which underpins device coatings and contract manufacturing through RUA Medical. The AurTex polymer heart valve, housed in RUA Structural Heart, is development-stage and not an approved product. Abiss contributes urogynaecology products.
Financial position
First-half revenue to 31 March 2026 was £2.75m at a gross margin of around 75%, with adjusted EBITDA of roughly positive £76,000. The group remains cash-flow negative at the operating and free-cash-flow level despite the growth, and its first-half operating loss, period-end cash and net debt are unverified.
What investors may be watching
Monitorable items include the return of core operations to profitability in the second half of the current financial year, the completion and financing of the structural-heart spin-out with its £10m valuation floor, Abiss revenue growth, and new manufacturing contracts.
Key risks
The group is very small in scale and under cash-flow pressure. There is execution and financing risk on the heart-valve spin-out, development and Regulatory Risk on early-stage device programmes, customer concentration in contract manufacturing, and micro-cap liquidity. Equity Development publishes investor-commissioned research on RUA, but no dated target is verified, so none is cited.
Poolbeg Pharma PLC (LSE:POLB)
Company overview
Poolbeg Pharma is a UK and Ireland-based clinical-stage biotech developing small-molecule and oral therapeutics, quoted on AIM and also on OTC as POLBF, and it is not verified as a current FTSE index constituent. Its lead asset is POLB 001, an oral p38 MAP-kinase inhibitor developed to prevent or reduce cytokine release syndrome associated with cancer immunotherapy, and drawing on a broad-spectrum anti-inflammatory heritage that includes prior severe-influenza work. Its second priority is an oral GLP-1 candidate for obesity. The company runs a capital-efficient development and partnering model, and no product is approved — all candidates are investigational. As of 31 August 2026 its market capitalisation was approximately £63m, on around 763m shares, making it a strong 2026 performer against a 52-week range of roughly 3.0p to 9.2p, with shares around 8.3p to 8.8p.
Latest September 2026 developments
On 13 July 2026 the company announced that the first patient had been dosed in the POLB 001 “TOPICAL” trial, an open-label study in cancer patients receiving immunotherapy across UK cancer centres including The Christie, the Royal Marsden, UCLH and University Hospitals Birmingham. On 14 July 2026 it announced a £3.5m placing of 58,333,328 shares at 6p, a roughly 16% discount to the 7.15p close on 13 July, with Executive Chair Cathal Friel subscribing £250,000. Cash was £4.8m on an unaudited basis at 30 June 2026 before the placing, which extends the cash runway into the second quarter of 2028. The company is debt-free, and proceeds fund the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial through to completion, plus partnering discussions.
Major 2026 developments
POLB 001 carries FDA Orphan Drug Designation, granted in 2025, and a granted European Patent in cancer-immunotherapy-induced CRS. Directors cite a potential market opportunity exceeding US$10bn, and partnering discussions with large and mid-sized pharmaceutical companies are ongoing. LPS-challenge data supporting POLB 001’s anti-inflammatory profile have been presented and published, including via PubMed and ASH.
Products, pipeline and technology
POLB 001, the oral p38 MAPK inhibitor for CRS in cancer immunotherapy, is in the open-label TOPICAL trial in immunotherapy-treated cancer patients, with interim data guided for summer 2026. An earlier Phase 1 LPS-challenge study was completed in healthy volunteers. The oral GLP-1 candidate for obesity is in a proof-of-concept trial in up to around 20 obese subjects at the University of Ulster; topline data were previously guided for the first half of 2026, and the July 2026 placing funds the trial through to completion, indicating it was still ongoing mid-2026. It is unverified whether topline had read out by 11 September 2026; it should be treated as a near-term milestone to monitor.
Financial position
Cash was £4.8m at 30 June 2026 on an unaudited basis, supplemented by £3.5m gross from the July 2026 placing. The company is debt-free with a stated runway into the second quarter of 2028. It is pre-revenue and loss-making, and its detailed first-half 2026 profit and loss, with interims typically reported in September, is unverified.
What investors may be watching
Monitorable catalysts include POLB 001 TOPICAL interim data, guided for summer 2026; the oral GLP-1 proof-of-concept topline, guided for the first half of 2026 with status to confirm; progress or closure of partnering or out-licensing discussions on POLB 001; and interim results for the six months to 30 June 2026, typically reported in September.
Key risks
As a pre-revenue biotech, Poolbeg carries clinical and development risk across investigational Assets with no approved products, and binary trial-data risk. It relies on securing a partner to fund late-stage development, faces financing and dilution risk typical of the sector despite the stated runway, and competes in crowded GLP-1 and CRS-mitigation landscapes.
What Should Investors Watch During the Rest of September 2026?
Several of the companies in this group have near-term events that are verifiable from their own disclosures, and these are the items worth following through the remainder of September 2026 and shortly beyond.
Kromek’s FY2026 audited results, for the year ended 30 April 2026, are expected in September 2026, the prior-year finals having been published on 16 September 2025. These will confirm whether the in-line revenue and profit-before-tax consensus cited in the May trading update has been met and will Fill in the gross-margin, EBITDA, cash and net-debt detail not yet disclosed.
ECO Animal Health holds its Annual General Meeting in September, at which non-executive director Frank Armstrong steps down, and investors will be watching for the US approval of ECOVAXXIN MS, which management expects by the end of the 2026 calendar year. An R&D day is planned for autumn 2026.
Abingdon Health’s FY2026 audited finals are expected around autumn 2026, and will provide the full-year audited gross profit, operating result and net-cash position behind the 31% revenue growth and second-half EBITDA break-even already flagged.
Poolbeg Pharma has two trial milestones to monitor. Interim data from the POLB 001 TOPICAL trial were guided for summer 2026, and topline data from the oral GLP-1 proof-of-concept trial were guided for the first half of 2026, though the status of that read-out is to be confirmed — the July 2026 placing funds the trial through to completion, indicating it was still ongoing mid-year. Interim results for the six months to 30 June 2026, typically reported in September, are also due.
AOTI’s defining potential event is the finalisation of the Medicare Local Coverage Determination, expected within approximately one year of the July 2026 proposal following a 45-day comment period. Management has been explicit that its growth trajectory will change materially only after the final LCD, so this is a medium-term rather than an immediate September catalyst.
For Applied Nutrition, Oxford BioDynamics and RUA Life Sciences, no specific September-2026-dated corporate event is confirmed in the available disclosures beyond those already reported — Applied Nutrition’s FY26 results on 26 August, Oxford BioDynamics’ shareholder-approved placing on 26 August, and RUA’s interim results on 30 June. Their next scheduled disclosures are not dated in the source material, and so are not stated here.
Conclusion
The common thread across these eight companies is not a shared prognosis but a shared position on the map: small-cap and micro-cap UK-listed health and life-sciences businesses, seven on AIM and one on the Main Market, each at a different point on the journey from technology to sustainable cash generation. What separates them is where they stand on that journey and how visible the next step is.
At one end sit the commercial cash generators. Applied Nutrition has delivered roughly 50% revenue growth to around £160m in FY26 and raised its FY27 outlook, making it the outlier in both scale and market venue. ECO Animal Health combines an established antibiotic franchise with a net-cash balance sheet and a vaccine pipeline it is positioning as a longer-term growth engine. AOTI is commercially established in US wound care but finds its trajectory tied to a single regulatory decision. In the middle are the businesses turning a corner on profitability — Abingdon Health reaching second-half EBITDA break-even, RUA Life Sciences returning to modestly positive adjusted EBITDA, and Kromek converting an order book against in-line consensus — where the question is durability rather than survival.
At the other end are the companies where the investment case is still being proven and financing is front of mind. Oxford BioDynamics has just completed a heavily dilutive rescue placing to secure at least twelve months of runway, and Poolbeg Pharma is advancing investigational assets toward binary read-outs on a funded runway into 2028. In both cases the technology is interesting and the commercial validation is incomplete.
For anyone following the sector, the rationale for monitoring these names lies in the concreteness of their near-term catalysts rather than in any expectation of a particular outcome. Kromek and Abingdon have audited results due; ECO Animal Health has an AGM and an awaited US vaccine approval; AOTI has a Medicare coverage process running its course; Poolbeg has trial data guided for the middle of the year. Each of these is a checkable event against which management’s commentary can be tested.
None of this constitutes advice, and none of these companies is without material risk — whether reimbursement dependence, going-concern pressure, antibiotic exposure, contract lumpiness, consumer-demand sensitivity or the inherent uncertainty of clinical trials. The sensible posture is to watch the scheduled disclosures as they arrive, weigh them against what each company has already told the market, and form a view from verifiable evidence rather than headline framing. “Top” here denotes companies of editorial interest in a busy corner of the UK market, not a ranking of likely returns.






Please wait processing your request...